Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients

Gilberto Filaci, Paola Contini, Sabrina Brenci, Paola Gazzola, Lorella Lanza, Marco Scudeletti, Francesco Indiveri, Giovanni Luigi Mancardi, Francesco Puppo

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Increased concentrations of soluble HLA class I and class II molecules (sHLA-I and sHLA-II) have been observed in infectious, inflammatory, and autoimmune diseases. Because autoimmune mechanisms are considered to play a role in the pathogenesis of multiple sclerosis (MS), we decided to dose sHLA- I and sHLA-II in serum and cerebrospinal fluid (CSF) of MS patients comparing their concentrations with those observed in serum and CSF of patients with other neurologic diseases (OND) without evidence of neuroradiologic involvement of central nervous system (CNS) and in serum of healthy donors. The serum concentrations of sHLA-I were higher in both MS and OND patients than in healthy donors (P <0.05) whereas sHLA-II serum concentrations were lower in MS patients than in both OND patients and healthy donors (P <0.01). Detectable amounts of sHLA-II were observed in the CSF of 45% of MS patients and in CSF of only 6% of OND patients (P <0.001). In MS patients a significant correlation between sHLA-I serum and CSF concentrations was observed (P <0.01), whereas sHLA-II serum and CSF levels did not correlate. In conclusion, alterations of sHLA-I and sHLA-II serum and CSF concentrations are present in MS patients and could be involved in the induction of enhanced susceptibility to develop MS or in MS pathogenesis.

Original languageEnglish
Pages (from-to)54-62
Number of pages9
JournalHuman Immunology
Volume54
Issue number1
DOIs
Publication statusPublished - Apr 15 1997

Fingerprint

Multiple Sclerosis
Cerebrospinal Fluid
Serum
Nervous System Diseases
Tissue Donors
Autoimmune Diseases
Communicable Diseases
Central Nervous System

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. / Filaci, Gilberto; Contini, Paola; Brenci, Sabrina; Gazzola, Paola; Lanza, Lorella; Scudeletti, Marco; Indiveri, Francesco; Mancardi, Giovanni Luigi; Puppo, Francesco.

In: Human Immunology, Vol. 54, No. 1, 15.04.1997, p. 54-62.

Research output: Contribution to journalArticle

Filaci, G, Contini, P, Brenci, S, Gazzola, P, Lanza, L, Scudeletti, M, Indiveri, F, Mancardi, GL & Puppo, F 1997, 'Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients', Human Immunology, vol. 54, no. 1, pp. 54-62. https://doi.org/10.1016/S0198-8859(97)00004-9
Filaci, Gilberto ; Contini, Paola ; Brenci, Sabrina ; Gazzola, Paola ; Lanza, Lorella ; Scudeletti, Marco ; Indiveri, Francesco ; Mancardi, Giovanni Luigi ; Puppo, Francesco. / Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. In: Human Immunology. 1997 ; Vol. 54, No. 1. pp. 54-62.
@article{571ddbb3ae664f599096aa504ae5c255,
title = "Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients",
abstract = "Increased concentrations of soluble HLA class I and class II molecules (sHLA-I and sHLA-II) have been observed in infectious, inflammatory, and autoimmune diseases. Because autoimmune mechanisms are considered to play a role in the pathogenesis of multiple sclerosis (MS), we decided to dose sHLA- I and sHLA-II in serum and cerebrospinal fluid (CSF) of MS patients comparing their concentrations with those observed in serum and CSF of patients with other neurologic diseases (OND) without evidence of neuroradiologic involvement of central nervous system (CNS) and in serum of healthy donors. The serum concentrations of sHLA-I were higher in both MS and OND patients than in healthy donors (P <0.05) whereas sHLA-II serum concentrations were lower in MS patients than in both OND patients and healthy donors (P <0.01). Detectable amounts of sHLA-II were observed in the CSF of 45{\%} of MS patients and in CSF of only 6{\%} of OND patients (P <0.001). In MS patients a significant correlation between sHLA-I serum and CSF concentrations was observed (P <0.01), whereas sHLA-II serum and CSF levels did not correlate. In conclusion, alterations of sHLA-I and sHLA-II serum and CSF concentrations are present in MS patients and could be involved in the induction of enhanced susceptibility to develop MS or in MS pathogenesis.",
author = "Gilberto Filaci and Paola Contini and Sabrina Brenci and Paola Gazzola and Lorella Lanza and Marco Scudeletti and Francesco Indiveri and Mancardi, {Giovanni Luigi} and Francesco Puppo",
year = "1997",
month = "4",
day = "15",
doi = "10.1016/S0198-8859(97)00004-9",
language = "English",
volume = "54",
pages = "54--62",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients

AU - Filaci, Gilberto

AU - Contini, Paola

AU - Brenci, Sabrina

AU - Gazzola, Paola

AU - Lanza, Lorella

AU - Scudeletti, Marco

AU - Indiveri, Francesco

AU - Mancardi, Giovanni Luigi

AU - Puppo, Francesco

PY - 1997/4/15

Y1 - 1997/4/15

N2 - Increased concentrations of soluble HLA class I and class II molecules (sHLA-I and sHLA-II) have been observed in infectious, inflammatory, and autoimmune diseases. Because autoimmune mechanisms are considered to play a role in the pathogenesis of multiple sclerosis (MS), we decided to dose sHLA- I and sHLA-II in serum and cerebrospinal fluid (CSF) of MS patients comparing their concentrations with those observed in serum and CSF of patients with other neurologic diseases (OND) without evidence of neuroradiologic involvement of central nervous system (CNS) and in serum of healthy donors. The serum concentrations of sHLA-I were higher in both MS and OND patients than in healthy donors (P <0.05) whereas sHLA-II serum concentrations were lower in MS patients than in both OND patients and healthy donors (P <0.01). Detectable amounts of sHLA-II were observed in the CSF of 45% of MS patients and in CSF of only 6% of OND patients (P <0.001). In MS patients a significant correlation between sHLA-I serum and CSF concentrations was observed (P <0.01), whereas sHLA-II serum and CSF levels did not correlate. In conclusion, alterations of sHLA-I and sHLA-II serum and CSF concentrations are present in MS patients and could be involved in the induction of enhanced susceptibility to develop MS or in MS pathogenesis.

AB - Increased concentrations of soluble HLA class I and class II molecules (sHLA-I and sHLA-II) have been observed in infectious, inflammatory, and autoimmune diseases. Because autoimmune mechanisms are considered to play a role in the pathogenesis of multiple sclerosis (MS), we decided to dose sHLA- I and sHLA-II in serum and cerebrospinal fluid (CSF) of MS patients comparing their concentrations with those observed in serum and CSF of patients with other neurologic diseases (OND) without evidence of neuroradiologic involvement of central nervous system (CNS) and in serum of healthy donors. The serum concentrations of sHLA-I were higher in both MS and OND patients than in healthy donors (P <0.05) whereas sHLA-II serum concentrations were lower in MS patients than in both OND patients and healthy donors (P <0.01). Detectable amounts of sHLA-II were observed in the CSF of 45% of MS patients and in CSF of only 6% of OND patients (P <0.001). In MS patients a significant correlation between sHLA-I serum and CSF concentrations was observed (P <0.01), whereas sHLA-II serum and CSF levels did not correlate. In conclusion, alterations of sHLA-I and sHLA-II serum and CSF concentrations are present in MS patients and could be involved in the induction of enhanced susceptibility to develop MS or in MS pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0030950288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030950288&partnerID=8YFLogxK

U2 - 10.1016/S0198-8859(97)00004-9

DO - 10.1016/S0198-8859(97)00004-9

M3 - Article

VL - 54

SP - 54

EP - 62

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 1

ER -